[Permanent venous access through a +portacath reservoir in patients receiving prolonged chemotherapy].
A significant number of oncology patients need intravenous chemotherapy. Peripheral venous access is generally difficult, frequently requiring central venous access. This study reviews the Author's experience with permanent venous portals. A total of 66 patients records, from January 1992 to April 1994, were reviewed. The central venous portals remained in place an average of 272 days. An average of 8 courses of chemotherapy were given through each port. There was no significant difference in the rate of complications secondary to the portal site. The Authors conclude that the placement of permanent venous portals is a safe and reliable chronic venous access in patients with cancer who require intravenous therapy. The rate of serious complication was 3% which is relatively low for these immunosuppressed patients. All venous portals, except one (98.5%) remained functional.
García
H
H
Servicio de Riesgo Profesional, Centro Médico Paitilla y en el Hospital de la Caja de Seguro Social.
Díaz
R
R
Pablo Barés
J
J
Nevah
E
E
Fábrega
J M
JM
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation*; D002408:Catheters, Indwelling / Q000009:adverse effects; D004867:Equipment Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
D000970:Antineoplastic Agents
Acceso venoso permanente mediante reservorio portacath en pacientes que reciben quimioterapia prolongada.